Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.60 |
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | PDE6D | O43924 | 1/20 | 0.58 |
| ▸ | TYMS | P04818 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | S100B | P04271 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1514286 | 0.90 | L3MBTL1 (0.73) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL14172750 | 0.82 | KMT2A (0.72) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL9290287 | 0.82 | PDE6D (0.82) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL5535530 | 0.81 | ATM (0.52) | KMT2AMEN1ALDH1A1L3MBTL1PDE6D | |
| SCHEMBL7825377 | 0.81 | TYMS (0.71) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL29549557 | 0.81 | TYMS (0.71) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL3841868 | 0.80 | L3MBTL1 (0.75) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL14510297 | 0.79 | KMT2A (0.59) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL16521562 | 0.79 | MEN1 (0.58) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL10869116 | 0.78 | PDE6D (0.81) | KMT2AMEN1KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1621531-B1 | Catayzed vapor-phase hydrocyanation of diolefinic compounds | INVISTA TECH SARL (US) | 2007-03-14 | — | — | EP | claimed |
| EP-1214290-B1 | MULTIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING THEM AND THEIR USE IN HYDROCYANATION REACTIONS | INVISTA TECH SARL (US) | 2006-11-02 | — | — | EP | claimed |
| EP-0891323-B1 | CATALYZED VAPOR-PHASE HYDROCYANATION OF DIOLEFINIC COMPOUNDS | INVISTA TECH SARL (US) | 2006-06-14 | — | — | EP | claimed |
| EP-1000020-B1 | HYDROCYANATION OF DIOLEFINS AND ISOMERIZATION OF NONCONJUGATED 2-ALKYL-3-MONOALKENENITRILES | DU PONT (US) | 2003-04-09 | — | — | EP | claimed |
| EP-1000021-B1 | HYDROCYANATION OF DIOLEFINS AND ISOMERIZATION OF NONCONJUGATED 2-ALYKL-3-MONOALKENENITRILES | DU PONT (US) | 2002-10-02 | — | — | EP | claimed |
| EP-0804412-B1 | HYDROCYANATION OF DIOLEFINS AND ISOMERIZATION OF NONCONJUGATED 2-ALKYL-3-MONOALKENENITRILES | DU PONT (US) | 1999-12-01 | — | — | EP | claimed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| WO-2007030939-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | KMT2A 4267/4885MEN1 3865/4885KDM4E 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.